Valneva SE (WBO:VLA) Common Stock : €24.4 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Valneva SE Common Stock?

Valneva SE's quarterly common stock increased from Jun. 2024 (€20.9 Mil) to Sep. 2024 (€24.3 Mil) and increased from Sep. 2024 (€24.3 Mil) to Dec. 2024 (€24.4 Mil).

Valneva SE's annual common stock increased from Dec. 2022 (€20.8 Mil) to Dec. 2023 (€20.8 Mil) and increased from Dec. 2023 (€20.8 Mil) to Dec. 2024 (€24.4 Mil).

Valneva SE Common Stock Historical Data

The historical data trend for Valneva SE's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Common Stock Chart

Valneva SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

13.65

15.79

20.76

20.84

24.38

Valneva SE Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															20.84	20.89	20.89	24.34	24.38

Valneva SE Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Valneva SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (WBO:VLA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

VALN:USA INRLF:USA 0OB3:UK VLA:France AYJ:Germany AYJ0:Germany AYJ0:Germany AYJ:Germany AYJ:Germany AYJ:Germany

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE Headlines

No Headlines